Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 60

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 60
---
 issued and outstanding shares of FutureTech Common Stock. Interests of Longevity’s and the Targets’ Directors and Executive Officers in the Business Combination The directors and executive officers of Longevity and the Targets have interests in the Business Combination that are different from, or in addition to, those of their respective equity holders. The Longevity Board was aware of and considered these interests, among other matters, in reaching the determination to approve the terms of the Business Combination. These interests include, among other things, the interests listed below:

| ● | Certain                                                                                     
 of the directors and executive officers of Longevity and the Targets are expected to become 
 directors and/or executive officers upon the Closing of the Business Combination.           |

| 15 |

Specifically, the following individuals who are currently executive officers of Longevity and the Targets are expected to become executive officers upon the Closing of the Business Combination, serving in the offices set forth opposite their names below:

| Name      |     | Position                        |
| Bradford  
 A. Zakes  |     | Chief                           
 Executive Officer and President |
| Francesco 
 Curra     |     | Chief                           
 Technology Officer              |
| Andrew    
 Leo       |     | Chief                           
 Quality Officer                 |

| ● | In                                                                                       
 addition, the following individuals are expected to become members of the Board upon the 
 closing of the Business Combination: [__].                                               |

| ● | Certain                                                                                         
 current executive officers and employees of Cerevast, who will become executive officers        
 of Longevity upon the Closing of the Business Combination, hold 459,784 options to acquire      
 common stock of Cerevast, which will be converted, in connection with the Business Combination, 
 into options to acquire an aggregate of 757,119 shares of FutureTech Common Stock at varying    
 exercise prices. See the section entitled “Executive and Director Compensation of               
 Longevity-Interests of Longevity’s and the Targets’ Directors and Executive Officers            
 in the Business Combination” for a further discussion.                                          |

| ● | Certain                                                                                     
 members of the Longevity board of directors, director nominees or entities controlled by    
 them, certain officers of Longevity, and certain anticipated officers will upon the closing 
 of the Target Acquisitions beneficially own, directly or indirectly, shares of Longevity    
 Common Stock and will be entitled to receive a portion of the consideration contemplated    
 by the Merger Agreement upon the consummation of the Business Combination. See the section  
 entitled “Beneficial Ownership of Securities” for a further discussion                      
 of the equity